Showing 1 - 8 of 8 reports matching: 2016 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases
Journals
Specialties
Date of Publication
to
Synopsis: 436 postmenopausal women with osteoporosis who had been administered oral bisphosphonate therapy for 3 years prior were randomized in a phase 3 clinical trial to subcutaneous romosozumab or subcutaneous teriparatide. The purpose of this study was to compare the change in bone mineral density after 1 year of treatment between the two groups. Reported results demonstrated Read More »
Conference Report
Synopsis: 540 postmenopausal women with normal to low bone mineral density were randomized to 24 months of treatment with either lasofoxifene 0.25mg/day, raloxifene 60mg/day, or daily placebo. The purpose of this study was to compare changes in bone mineral density and bone turnover markers between groups after 24 months of treatment. Change in bone Read More »
Conference Report
Synopsis: A subset of 164 women from the Long-Term Odanacatib Fracture Trial were included in this imaging sub-study to evaluate the effect of odanacatib versus placebo on volumetric bone mineral density (vBMD) of the lumbar spine and total hip. Follow-up was made at 24 months of treatment, and percent change in trabecular vBMD of the lumbar spine and cortical vBMD of total hip were compared. Results demonstrated a Read More »
Conference Report
Synopsis: 643 postmenopausal women with osteoporosis who had been administered oral bisphosphonates for 2 or more years prior to enrollment were randomized to be administered either denosumab or zoledronic acid. The purpose of this study was to compare the change in bone mineral density (BMD) and bone turnover markers after 1 year. Results demonstrated a Read More »
Conference Report
Synopsis: 12483 women, 70-85 years of age, were randomized to either a screening program, using the FRAX algorithm to estimate fracture risk, or to usual care (control). The purpose of this study was to evaluate the efficacy of the screening program on reducing the 5-year fracture incidence. Results demonstrated no Read More »
Conference Report
Synopsis: 96 elderly women with osteoporosis and back pain, with or without vertebral fracture, were randomized to one of three groups. Participants received either a spinal orthosis, a training program, or usual care. Participants were assessed Read More »
Conference Report
Synopsis: 80 patients with osteoporosis were randomized to receive either alfacalcidol, a vitamin D analogue, or plain vitamin D (cholecalciferol). Both treatment groups also received calcium supplementation and alendronate. The purpose of Read More »
Conference Report
Synopsis: 2463 postmenopausal women with osteoporosis were randomized to one of three groups: daily subcutaneous abaloparatide (80ug), daily subcutaneous teriparatide (20ug), or daily subcutaneous placebo. The treatment period was 18 months, and patients were assessed for bone mineral density and incident fracture rate. Abaloparatide treatment was Read More »
Conference Report